Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Narcolepsy - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Narcolepsy - Pipeline Review, H1 2015', provides an overview of the Narcolepsy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Narcolepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Narcolepsy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Narcolepsy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Narcolepsy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Narcolepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Narcolepsy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Narcolepsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Narcolepsy Overview 7 Therapeutics Development 8 Pipeline Products for Narcolepsy - Overview 8 Pipeline Products for Narcolepsy - Comparative Analysis 9 Narcolepsy - Therapeutics under Development by Companies 10 Narcolepsy - Therapeutics under Investigation by Universities/Institutes 11 Narcolepsy - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Narcolepsy - Products under Development by Companies 15 Narcolepsy - Products under Investigation by Universities/Institutes 16 Narcolepsy - Companies Involved in Therapeutics Development 17 Bioprojet SCR 17 Evotec AG 18 Flamel Technologies S.A. 19 Grupo Ferrer Internacional, S.A. 20 Jazz Pharmaceuticals plc 21 SK Biopharmaceuticals Co., Ltd. 22 Taisho Pharmaceutical Co., Ltd. 23 Narcolepsy - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 30 Drug Profiles 31 arbaclofen - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Drugs to Agonize Orexin Receptor for Narcolepsy - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 EVT-501 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 JZP-386 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 pitolisant - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 SKL-N05 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Agonize Orexin Receptor for Narcolepsy and EDS - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 sodium oxybate - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 sodium oxybate - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 THN-102 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 TS-091 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Narcolepsy - Recent Pipeline Updates 46 Narcolepsy - Dormant Projects 49 Narcolepsy - Discontinued Products 50 Narcolepsy - Product Development Milestones 51 Featured News & Press Releases 51 May 07, 2015: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update 51 Dec 19, 2014: Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump Sodium Oxybate 51 Dec 09, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update 52 Dec 02, 2014: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy 52 Jul 21, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386 53 Jun 02, 2014: Jazz Pharmaceuticals Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy 53 May 27, 2014: Jazz Pharmaceuticals To Present Data On Compound In Sleep Pipeline During APSS Annual SLEEP Meeting 54 May 07, 2014: Sleep Researchers at SRI International Identify Promising New Treatment for Narcolepsy 54 Apr 07, 2014: Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate 55 Jun 03, 2013: Aerial BioPharma Announces Presentation Of ADX-NO5 Results At SLEEP 2013 Meeting 56 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Number of Products under Development for Narcolepsy, H1 2015 8 Number of Products under Development for Narcolepsy - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Number of Products under Investigation by Universities/Institutes, H1 2015 11 Comparative Analysis by Late Stage Development, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Products under Investigation by Universities/Institutes, H1 2015 16 Narcolepsy - Pipeline by Bioprojet SCR, H1 2015 17 Narcolepsy - Pipeline by Evotec AG, H1 2015 18 Narcolepsy - Pipeline by Flamel Technologies S.A., H1 2015 19 Narcolepsy - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 20 Narcolepsy - Pipeline by Jazz Pharmaceuticals plc, H1 2015 21 Narcolepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 22 Narcolepsy - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 23 Assessment by Monotherapy Products, H1 2015 24 Number of Products by Stage and Target, H1 2015 26 Number of Products by Stage and Mechanism of Action, H1 2015 28 Number of Products by Stage and Route of Administration, H1 2015 29 Number of Products by Stage and Molecule Type, H1 2015 30 Narcolepsy Therapeutics - Recent Pipeline Updates, H1 2015 46 Narcolepsy - Dormant Projects, H1 2015 49 Narcolepsy - Discontinued Products, H1 2015 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.